Iselin, New Jersey
San Francisco, CA
Posters for Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be presented on Friday, October 5, 2018 in S Poster Hall from 12:30pm to 1:45pm PT.
President and CEO, Christopher J. Burns, Ph.D., and Senior Vice President, Business and Corporate Development, Tony Meehan, Ph.D. will be attending.
New York, NY
President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of Venatorx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.
Tony Meehan, Ph.D., Senior Vice President, Business and Corporate Development, is participating on a panel entitled, "Partnering with big pharma - Will you hit the jackpot or lose it all?" on Thursday, May 10, 2018 at 3:00pm ET at the Hilton Philadelphia City Avenue.
Fourteen poster presentations, including four oral sessions, will feature Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at ECCMID in Madrid, Spain. In addition, Venatorx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.
Christopher J. Burns, Ph.D., President and CEO, will participate on a panel entitled, "Panel – Man vs. Microbe," which will take place on April 5, 2018 at 10:30am ET at the St. Regis Hotel in Washington, DC.
New Orleans, LA
Christopher J. Burns, Ph.D., President and CEO, will present Venatorx Pharmaceuticals' lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium on March 21, 2018 at 3:15pm CT in New Orleans, LA. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”